Advocacy


The UKMF is actively involved in NICE consultations regarding new technologies at all stages of the appraisal process, providing feedback on draft scopes and documents, attending workshops and appraisal meetings.  We also put together submissions on new technologies when invited, summarising the treatment landscape of myeloma and the impact of the new technology.  Together with MyelomaUK, we are working towards stream-lined treatment pathways for UK myeloma patients that are practicable, reflect current ‘best practice’ internationally, and take into account disease and patient specific factors. We are keen to involve patients and patient and carer groups in consultation processes, and again, work closely with MyelomaUK to achieve this. The lead for Advocacy is currently Dr Matthew Streetly.

UKMF Advocacy Report  Nov 2020, Prepared by M Streetly, Advocacy Lead UKMF

Completed / FAD issued

Isatuximab (ID1477)

  • Rel / Refr myeloma
  • In combination with pomalidomide / dex
  • UKMF rep: GC / MS
  • FAD 15/10/20: approved via CDF

Carfilzomib (Part rev TA457)

  • Relapsed myeloma
  • In combination with lenalidomide / dex or dex
  • UKMF rep: KR
  • FAD 22/10/20: no change to recommendation i.e. Car+ Len+dex not approved

Ongoing Appraisals

Daratumumab (ID1510)

  • 1st line, transplant eligible
  • In combination with VTD
  • UKMF rep: NR
  • 1st appraisal meeting: 4/3/21

Idecabtagene Vicleucel (ID1442)

  • Rel/Ref myeloma
  • >= 3 prior lines
  • UKMF rep: MS/KY
  • Comments: 8/12/20
  • 1st appraisal meeting: 16/6/21

Lenalidomide maintenance post autograft (ID475)

  • UKMF reps: KR / GP
  • 1st Committee meeting: 08/2020
  • ACD (due 09/2020): not supported
    • Response from KR / MJ
  • 2nd appraisal meeting: 12/11/20

Selinexor (ID3797)

  • Rel/Refr myeloma
  • In combination with bortez/ Dex
  • UKMF reps: NR/JA

Next steps awaited / or suspended

Carfilzomib / daratumumab / dex (ID270)

  • Rescheduled pending data
  • Estimated to start May 2021
  • UKMF rep: KR

Selinexor (ID1535)

  • Rel/Refr myeloma
  • In combination with Dex
  • UKMF reps: NR/JA
  • Responses due by 23/9/20

 Isatuximab (ID1620)

  • Rel/refr
  • In combination with carfilzomib / dex
  • Responses by 19/11/20
  • Manufacturer not submitting